Tests PBGENE-HBV in adults with chronic hepatitis B
Tests PBGENE-HBV for safety and antiviral effect in adults with chronic hepatitis B.
Plain-language title generated from the registry record
Registry title: Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B
Key facts
- Where
- Chisinau, MoldovaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 70 with HBeAg-negative chronic hepatitis B whose virus is already suppressed on nucleoside analogue (NA) treatment.
- Age
- 18 to 70 years
- Sex
- Men, and women who cannot have children. The registry lists all sexes.
- Disease stage
- Chronic hepatitis B (CHB) documented at least 12 months before screening, HBeAg-negative. No history of cirrhosis of the liver.
- Earlier treatment
- Must be virologically suppressed on current NA treatment. No investigational agent within 6 months of screening.
- Biomarker or test result
- HBeAg-negative chronic hepatitis B. BMI 18.0 to 35.0.
Main reasons for not taking part
- History of cirrhosis of the liver
- Current infection with hepatitis A, D or E, HIV type 1 or 2, or current or past hepatitis C
- Signs of hepatocellular carcinoma
- Organ transplant received
- Malignancy within 5 years of screening, with some exceptions such as basal cell skin cancer
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06680232, who can take part
Where in Moldova
- ICS ARENSIA Exploratory Medicine SRLChisinau, MoldovaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Precision BioSciences, Inc.
- Trial code
- NCT06680232EU 2025-524157-13-00
- Record updated
- 24 August 2026
- Original description
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.Read full original descriptionShow less
A Phase 1, Open-Label, First-in-Human, Dose Escalation (Part 1) and Expansion (Part 2) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of PBGENE-HBV in Participants With Chronic Hepatitis B (ELIMINATE-B)
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
Inclusion: Male or women of non-child bearing potential; BMI 18.0 to 35.0; Good overall health deemed by the study Investigator; CHB infection documented at least 12 months prior to screening; HBeAg-negative CHB; Must be virologically suppressed on current NA treatment.
Exclusion: Not received an organ transplant; No investigational agent received within 6 months of screening; No history of cirrhosis of the liver; No current infections of Hepatitis A, D, and E, human immunodeficiency virus (type 1 and 2), and no history of or current hepatitis C. In addition, no other active infections deemed clinically relevant; No malignancy within 5 years of screening, except for specific cancers that are cured by surgical resection (e.g., basal cell skin cancer); No signs of hepatocellular carcinoma.